hephaistos.bio secures €161K to advance sustainable chemical manufacturing
What's the deal? Swiss startup hephaistosDealroom has a profile for this one. Try Dealroom →.bio has secured €161,000 (US$137.5K) from Venture KickDealroom has a profile for this one. Try Dealroom → to develop custom enzyme solutions for pharmaceutical and chemical manufacturing. The company combines computational biology, chemistry, machine learning, and structural biology to design protein catalysts tailored to specific industrial processes.
Founded by a five-person team spanning chemistry, biotechnology, and machine learning, the startup has already launched an industrial pilot with Swiss contract research organisation SpiroChemDealroom has a profile for this one. Try Dealroom →.
The funding will go toward follow-up enzyme design campaigns, expanding laboratory automation, and making the company's first hires.
Why now? Chemical manufacturing still depends on energy- and resource-intensive processes that generate significant emissions and leave producers exposed to fragile global supply chains. Enzymes can make production more efficient, cheaper, and cleaner — but suitable biocatalysts simply don't exist for many industrially relevant reactions, particularly in pharma.
hephaistos.bio's end-to-end platform creates biocatalysts for reactions that are difficult or impossible to perform efficiently with existing solutions. The startup says it wants to help pharmaceutical and fine chemical companies reshore production to Europe through more competitive, enzyme-enabled manufacturing.
What could go wrong? At €161,000, this is a very early-stage bet. Custom enzyme design is technically demanding, and the gap between a promising pilot and scalable commercial adoption can be wide. Competing with established chemical processes — even inefficient ones — requires not just better science but also regulatory acceptance and manufacturer willingness to overhaul production workflows.
The signal: Venture Kick, a Swiss investment fund focused on early-stage startups, has a track record of backing deep-tech founders at the pre-seed stage — making this grant a validation checkpoint rather than a scale-up bet. hephaistos.bio's positioning at the intersection of AI-driven protein engineering and industrial decarbonisation aligns with a broader wave of European investment into computational biology platforms, as pharma and chemical manufacturers face mounting pressure to cut emissions and reduce supply-chain dependence on Asia.
Read more: tech.eu
